James Mock, an insider at Moderna Inc (MRNA), sold 43,200 shares of the company's stock on December 4, 2025, at a price of $25.49 per share, totaling approximately $1.10 million. Following this transaction, Mock retains an equal number of shares in the biotechnology firm.
Moderna, headquartered in Cambridge, Massachusetts, specializes in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company has made significant strides in its pipeline, which includes 44 therapeutic and vaccine programs, with 11 currently in late-stage development. Among its commercial products are Spikevax, its COVID-19 vaccine, and mRESVIA, targeting respiratory syncytial virus (RSV).
The market capitalization of Moderna stands at $10.0 billion, with a trailing twelve-month earnings per share (EPS) of -8.05. Investors are awaiting upcoming earnings reports, with estimates of -$2.37 EPS and $117.6 million in revenue for July 30, 2026, and -$2.40 EPS with $218.2 million in revenue expected for April 29, 2026.
Insider transactions, such as Mock's recent sale, are reported to the SEC to maintain transparency regarding the actions of company executives. While such sales can occur for various reasons, including diversification and personal financial needs, they do not necessarily reflect negative sentiments about the company. Investors are encouraged to analyze insider activity across multiple individuals and timeframes to gain a clearer perspective on market signals.